This review highlights the evidence-based data to support current best management
practices for patients with recurrent and/or metastatic (R/M) head and neck squamous cell …

Head and neck cancer (HNC) broadly includes carcinomas arising from the mucosal
epithelia of the head and neck region as well as various cell types of salivary glands and the …

Purpose: The genetic differences between human papilloma virus (HPV)–positive and–
negative head and neck squamous cell carcinomas (HNSCC) remain largely unknown. To …

Over the last two decades, it has been recognized that head and neck cancers, primarily in
the oropharynx, can be a distinct entity that is causally related to human papilloma virus …

Due to the generally poor prognosis of head and neck squamous cell carcinoma (HNSCC),
treatment has been intensified, these last decades, leading to an increase of serious side …

Background We aimed to compare panitumumab, a fully human monoclonal antibody
against EGFR, plus radiotherapy with chemoradiotherapy in patients with unresected, locally …

Background Panitumumab is a fully human monoclonal antibody that targets EGFR. We
aimed to compare chemoradiotherapy plus panitumumab with chemoradiotherapy alone in …

Head and neck cancer is the fifth most common cancer worldwide. It is often amenable to
curative intent therapy when localized to the head and neck region, but it carries a poor …

Background Cetuximab in combination with platinum and 5-fluorouracil is the standard of
care in the first-line treatment of patients with recurrent/metastatic head and neck squamous …

Importance Human papillomavirus–related oropharyngeal carcinoma (HPV-OPC) is
increasing in incidence in the United States. Although HPV-OPC has favorable prognosis …